About OPi Group
OPi Group is a company based in Dardilly (France) founded in 1999 was acquired by EUSA Pharma in March 2007. OPi Group operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Mereo BioPharma and Amicus Therapeutics, among others.
- Headquarter Dardilly, France
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Acquired by
EUSA Pharma
(Mar 01, 2007)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of OPi Group
Detailed funding history for OPi Group
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in OPi Group
OPi Group has secured backing from 1 investor. Prominent investors backing the company include EUSA Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Developer and commercializer of pharmaceutical medicines
|
Locked | Locked | Locked |
Investor details for OPi Group
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OPi Group
Investment portfolio details for OPi Group
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - OPi Group
Detailed financials for OPi Group
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Opi Group Comparisons
Peer comparison for OPi Group
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OPi Group
OPi Group operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Mereo BioPharma and Amicus Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of therapies for rare and orphan diseases
|
|
| Locked | Locked | Locked |
Developer of therapeutics to treat rare genetic diseases
|
Detailed competitors of OPi Group
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Opi Group
Complete news archive for OPi Group
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OPi Group
OPi Group was founded in 1999.
OPi Group is headquartered in Dardilly, France. It is registered at Dardilly, Rhone, France.
Enzymatic therapeutics targeting rare and severe diseases are developed by OPi Group, which was founded in 1999 and is based in Dardilly, France. Operations focus on biotechnology within the pharmaceutical sector, with specific products including Kidrolase, derived from Escherichia coli L-asparaginase, and Erwinase, derived from Erwinia chrysanthemi L-asparaginase. These are utilized for patient treatment in orphan disease indications.
OPi Group's top competitors include Moderna, Spark Therapeutics and BridgeBio.
OPi Group has 1 investor. Key investors include EUSA Pharma.